Appointment of Mark Gardner as President

GeneDx Holdings Corp. announced the appointment of Mark Gardner as President, effective June 15, 2026. Gardner will oversee the company's lab and commercial operations, reporting to CEO Katherine Stueland. He previously served as Senior Vice President of Molecular Genomics and Oncology at Quest Diagnostics. Gardner's employment agreement includes a base salary of $530,000, a target annual bonus of 65%, and restricted stock units valued at $2,000,000, vesting over four years. The agreement provides for severance benefits in case of termination without cause or resignation for good reason, with enhanced benefits in the event of a change in control. Bryan Dechairo will transition to a role focused on product, technology, and innovation initiatives. The company also issued a press release on June 16, 2026, announcing Gardner's appointment.